

Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 08TH August, 2025

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Outcome of the Board Meeting of the Company

Ref: Compliance of Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 08th August, 2025, at 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi-110020, approved the following businesses:

Financial Results

1. Unaudited Financial Results (Consolidate & Standalone) for the First quarter ended on 30th June 2025.

A signed copy of the above Financial Results (Standalone & Consolidated) along with Auditors' Review Reports thereon is attached herewith as "Annexure - A"

Appointment of Director(s)

2. Re-appointment of Mr. Amit Khosla (DIN: 00203571) as a Non-Executive Independent Director of the Company, for a period of five (5) consecutive years commencing from Conclusion of 30th Annual General Meeting of the Company, subject to approval of Members of the Company at the ensuing AGM.
3. Re-appointment of Ms. Sonal Mattoo (DIN: 00106795) as a Non-Executive Independent Director of the Company, for a period of Five (5) consecutive years commencing from Conclusion of 30th Annual General Meeting of the Company, subject to approval of Members of the Company at the ensuing AGM.

Further, please take note that Mr. Amit Khosla and Ms. Sonal Mattoo are not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority.

The disclosure(s) with respect to the above re-appointment(s), as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as Annexure - B.

Plants : Plot No. 104-105 & 115-116, Sector-59, HSIIDC Industrial Area, Ballabgarh, Faridabad - 121004, Haryana (INDIA)
Plot No. 33-34, Sector-68, IMT, Faridabad - 121004, Haryana (INDIA) T : +91-129-4287000, 3355070



4. Appointment of Mr. Pankaj Kumar Gupta (DIN: 11232604) as an Executive Director of the Company for a period of Five (5) consecutive years commencing from August 08, 2025, subject to approval of Members of the Company at the ensuing AGM.

Further, please take note that Mr. Pankaj Kumar Gupta are not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority.

The disclosure(s) with respect to the above re-appointment(s), as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as **Annexure - C**.

Grant of Stock Options

5. Nomination & Remuneration Committee, approved grant of 3,400 (Three Thousand Four Hundred Only) Stock Options under the Poly Medicure Limited Employee Stock Option Scheme 2020, to eligible employees.

The disclosure(s) as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 for the above mentioned ESOP Grant is enclosed herewith as **Annexure - D**.

Re-appointment of Cost Auditors

6. Re-appointment of M/s Jai Prakash & Company as the Cost Auditors of the Company for the Financial Year 2025-26.

The disclosure(s) with respect to the above re-appointment(s), as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as **Annexure - E**.


7. Any Other Item.

The Meeting was started at 11.30 A.M. and concluded on 2:15 P.M.

Kindly take a note of the same for your further needful and oblige us.

Thanking You,
Yours Sincerely

For Poly Medicure Limited


Avinash Chandra
Company Secretary
M. No. A32270





POLY MEDICURE LIMITED


Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020

Website: www.polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(₹ in lacs except per share data)

	Particulars	Standalone			Consolidated			Standalone	Consolidated
		Quarter Ended			Quarter Ended			Year Ended	Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)	31.03.2025 (Audited)
1	Income								
a	Revenue from operations	38,404.67	42,096.94	36,742.47	40,321.07	44,082.82	38,477.64	1,60,179.98	1,66,983.16
b	Other income	4,109.55	2,394.86	1,683.15	4,169.09	2,430.95	1,691.91	8,977.24	8,912.76
	Total income(A)	42,514.22	44,491.80	38,425.62	44,490.16	46,513.77	40,169.55	1,69,157.22	1,75,895.92
2	Expenses								
a	Cost of materials consumed	12,874.86	13,512.09	12,529.85	14,107.35	14,195.46	13,257.17	54,087.63	57,136.26
b	Purchases of stock-in-trade	85.85	251.41	89.26	85.85	251.22	89.26	792.90	793.91
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(755.28)	628.19	(510.69)	(1,470.17)	292.63	(520.47)	(1,703.63)	(2,461.15)
d	Employee benefits expense	6,993.06	7,197.88	6,511.93	7,511.40	7,889.08	6,951.09	28,008.36	30,153.20
e	Research and development expenses	665.90	659.72	556.73	668.05	661.62	556.81	2,453.46	2,457.11
f	Finance cost	281.38	216.65	297.99	295.01	216.73	316.20	1,140.69	1,199.65
g	Depreciation and amortisation expense	2,284.23	2,133.08	1,885.32	2,325.76	2,102.92	1,952.72	8,083.90	8,263.60
h	Other expenses	8,377.81	8,243.15	7,457.70	8,804.71	8,846.71	7,764.43	32,004.81	33,619.84
	Total expenses(B)	30,807.81	32,842.17	28,818.09	32,327.96	34,456.37	30,367.21	1,24,868.12	1,31,162.42
3	Profit from operations before exceptional items (A-B)	11,706.41	11,649.63	9,607.53	12,162.20	12,057.40	9,802.34	44,289.10	44,733.50
4	Exceptional Items								
5	Share of Profit of an associate	-	-	-	132.43	227.52	43.39	-	518.01
6	Profit before tax	11,706.41	11,649.63	9,607.53	12,294.63	12,284.92	9,845.73	44,289.10	45,251.51
7	Tax expense								
a	Current tax	2,130.98	2,231.29	2,204.27	2,206.81	2,379.19	2,268.78	9,290.10	9,560.27
b	Deferred tax	782.54	751.70	173.01	779.53	721.69	173.01	1,855.34	1,825.33
c	Earlier Year Taxes	-	0.62	-	-	0.62	-	10.19	10.19
	Total Tax Expense	2,913.52	2,983.61	2,377.28	2,986.34	3,101.50	2,441.79	11,155.63	11,395.79
8	Profit after tax	8,792.89	8,666.02	7,230.25	9,308.29	9,183.42	7,403.94	33,133.47	33,855.72
9	Other Comprehensive Income								
	Items that will not be reclassified to profit or loss :								
	Remeasurements of defined benefit obligations	(117.32)	(5.29)	(172.69)	(117.32)	(5.29)	(172.69)	(206.75)	(206.75)
	Tax impacts on above	29.53	1.33	43.47	29.53	1.33	43.47	52.04	52.04
	Items that will be reclassified to profit or loss in subsequent period:								
	Exchange differences on translation of financial statements of foreign Subsidiaries	-	-	-	19.07	18.07	(8.36)	-	19.24
	Tax impacts on above	-	-	-	-	-	-	-	-
	Total Other Comprehensive Income	(87.79)	(3.96)	(129.22)	(68.72)	14.11	(137.58)	(154.71)	(135.47)
10	Total comprehensive income (comprising profit after tax and other comprehensive income after tax)	8,705.10	8,662.06	7,101.03	9,239.57	9,197.53	7,266.36	32,978.76	33,720.25
11	Net Profit attributable to:								
	Equity holders of the parent	-	-	-	9,308.29	9,183.42	7,403.94	-	33,855.72
	Non-controlling interests	-	-	-	-	-	-	-	-
12	Other Comprehensive income attributable to:								
	Equity holders of the parent	-	-	-	(68.72)	14.11	(137.58)	-	(135.47)
	Non-controlling interests	-	-	-	-	-	-	-	-
13	Total comprehensive income attributable to:								
	Equity holders of the parent	-	-	-	9,239.57	9,197.53	7,266.36	-	33,720.25
	Non-controlling interests	-	-	-	-	-	-	-	-



14	Paid-up equity share capital (Face Value of ₹ 5 each)	5,066.29	5,066.29	4,798.58	5,066.29	5,066.29	4,798.58	5,066.29	5,066.29
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year		-		-	-	-	2,69,355.60	2,71,499.50
16	Earnings per share (Quarterly not annualised) :								
	Basic (₹)	8.68	8.40	7.53	9.19	8.92	7.71	33.40	34.13
	Diluted (₹)	8.67	8.40	7.53	9.17	8.92	7.71	33.39	34.11

Notes:

- The above unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 08th August, 2025 and have also been limited reviewed by Statutory auditors of the company. The statutory auditors have expressed an unmodified review report on these standalone and consolidated financial results.
- The standalone and consolidated financial results have been prepared in accordance with the principles and procedures of Indian Accounting Standards ("Ind AS") as notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act, 2013.
- The Consolidated unaudited Financial Results of the Company and its Foreign Subsidiaries/Indian subsidiary ("Group") and associate have been prepared as per IND AS 110 "Consolidated Financial statements" and IND AS 28 on "Investment in Associates". The following entities have been considered in Consolidated quarterly financial results.
 - Poly Medicure (Laiyang) Co. Ltd – Wholly owned Subsidiary (Management Certified)
 - Poly Medicure B V – Netherlands(Consolidated) – Wholly owned Subsidiary (Management certified)
 - Plan 1 health India Pvt Ltd.- Wholly owned Subsidiary (Management Certified)
 - Ultra for Medical Products Co.(UMIC) Egypt – Associate (Management Certified)
- The financial results include the results for the quarter ended March 31, 2025 being the balancing figures between the audited figures in respect of full financial year ended 31st March 2025 and the published unaudited year to date figures upto the third quarter of the previous financial year.
- In line with the provisions of Ind AS 108- Operating Segments and on the basis of review of operations being done by the management of the Company, the operations of the group falls under medical devices, which is considered to be the only reportable segment by the management.
- During the year ended 31st March, 2025, the company had issued 53,19,148 equity shares of Rs 5/- each at premium of Rs. 1875/- each (Issue Price per share Rs. 1880/- each) amounting to Rs.999,99.98 lacs to Qualified Institutional Investors on QIP basis and allotment was completed on 22nd August 2024. The proceeds of QIP have been utilized as per details given below as on 30th June 2025:

S.No	Particulars	Amount (₹ in lacs)
1	QIP share issue expenses	1,465.61
2	Repayment of working capital limits and for general corporate purposes	10,740.11
3	Amount temporarily invested in liquid mutual funds pending utilization	85,432.29
4	Capital expenditure	2,032.34
5	Bank balance in QIP account	329.63
	Total	99,999.98

- During the Quarter ended 30th June 2025, 97,526 numbers of Equity shares of Rs.5 each have been granted to eligible employees as per ESOP 2020 at an exercise price of Rs.100 per share.
- Previous period figures have been regrouped wherever necessary to conform to the current year classification.
- The unaudited results of Poly Medicure Limited for the Quarter ended 30th June 2025 are available on our website, www.polymedicure.com and on the Stock Exchange website www.nseindia.com and www.bseindia.com

Place : New Delhi
Date : 08th August 2025



Himanshu Baid
Managing Director

POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020,
Website: www.polymedicure.com, E-mail: Investorcare@polymedicure.com, CIN: L40300DL1995PLC066923
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER JUNE 30, 2025

(₹ in lacs except per share data)

	Particulars	Standalone			Consolidated		
		Quarter Ended	Quarter Ended	Year Ended	Quarter Ended	Quarter Ended	Year Ended
		30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)	30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Total Income from operations	42,514.22	38,425.62	1,69,157.22	44,490.16	40,169.55	1,75,895.92
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	11,706.41	9,607.53	44,289.10	12,294.63	9,845.73	45,251.51
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	11,706.41	9,607.53	44,289.10	12,294.63	9,845.73	45,251.51
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	8,792.89	7,230.25	33,133.47	9,308.29	7,403.94	33,855.72
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	8,705.10	7,101.03	32,978.76	9,239.57	7,266.36	33,720.25
6	Equity paid up share capital	5,066.29	4,798.58	5,066.29	5,066.29	4,798.58	5,066.29
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year			2,69,355.60	-		2,71,499.50
8	Earnings per share (Face Value of ₹ 5 each) (Quarterly not annualised) :						
	Basic (₹)	8.68	7.53	33.40	9.19	7.71	34.13
	Diluted (₹)	8.67	7.53	33.39	9.17	7.71	34.11

- The above unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 08th August, 2025 and have also been limited reviewed by Statutory auditors of the company.
- The above is an extract of the detailed format of unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com.

Place : New Delhi

Date : 08th August 2025



Himanshu Baid
Managing Director



DOOGAR & ASSOCIATES

Chartered Accountants

Independent Auditors' Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To

Board of Directors

Poly Medicure Limited

232-B, IIIrd Floor,

Okhla Industrial Estate, Phase-III,

New Delhi- 110020

We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medicure Limited ("the company") for the quarter ended 30th June 2025 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.


A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates

Chartered Accountants

Firm Registration No. 000561N


Madhusudan Agarwal
Partner

Membership No. 086580

UDIN: 25086580 BMMATW1582



Place: New Delhi

Date: 08th August 2025

13, Community Centre, East of Kailash, New Delhi - 110065

E-mail : client@doogar.com, admin@doogar.com, Website : www.doogar.com

Ph. : 011-46579759, 41051966, 47037656

Branches at : Mumbai and Agra



Scanned with OKEN Scanner

DOOGAR & ASSOCIATES

Chartered Accountants

Independent Auditors' Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
Board of Directors
Poly Medicure Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Poly Medicure Limited ("Parent") and its subsidiaries (the parent and its subsidiaries together referred to as 'the group') and its share of the profit after tax of its associate for the quarter ended 30th June 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended ('the Regulation'), read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Regulation, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the statement.
5. We did not review the financial results of 2 foreign subsidiaries and one subsidiary incorporated in India included in the consolidated unaudited financial results, whose financial results reflect total revenues of Rs 2,444.88 Lacs, total net profit/ (loss) after tax of Rs 382.96 Lacs, for the quarter ended 30th June 2025, as considered in the consolidated unaudited financial results.
The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs. 132.43 lacs, for the quarter ended 30th June 2025, as considered in the statement, in respect of one foreign associate, whose financial results have not been reviewed by us.



13, Community Centre, East of Kailash, New Delhi - 110065

E-mail : client@doogar.com, admin@doogar.com, Website : www.doogar.com

Ph. : 011-46579759, 41051966, 47037656

Branches at : Mumbai and Agra




These financial results are certified by the management of respective companies and our conclusion on the Statement in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the basis of financial statement as certified and procedures performed by us as stated in paragraph 3 above. Our conclusion on the statement is not modified in respect of above matter.

6. In respect of subsidiaries and associate located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and are management certified. The Parent's management has converted the financial results of such subsidiaries and associate located outside India from accounting principles generally accepted in their respective countries to the accounting principles generally accepted in India. We have reviewed conversion adjustment made by the parent's management. Our conclusion in so far as it relates to balances and affairs of such subsidiaries and associate located outside India is based on the conversion adjustments prepared by the management of the Parent and reviewed by us.
7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial statements as certified by the management referred to paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid in the aforesaid Indian Accounting Standard specified under Section 133 of Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates

Chartered Accountants


Firm's Registration number: 000561N


Madhusudan Agarwal

Partner

Membership number: 086580

UDIN: 25086580 BMM ACX 2297



Place: New Delhi

Date: 08th August 2025

Annexure I: List of entities consolidated as at June 30, 2025

1. Poly Medicure (Laiyang) Co. Ltd.- China - Wholly owned Subsidiary.(Management Certified)
2. Poly Medicure BV - Netherlands (Consolidated) - Wholly owned Subsidiary (Management Certified)
3. Ultra for Medical Products Co. (UMIC) - Egypt - Associate (Management Certified)
4. Plan 1 Health India Pvt. Ltd. (Management Certified)



Annexure- B

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

Sr. No.	Particulars	Mr. Amit Khosla (Independent Director)	Ms. Sonal Mattoo (Independent Director)
1.	Reason for change viz. appointment/re-appointment, resignation, removal, death or otherwise	Mr. Amit Khosla, DIN: 00203571 is being re-appointed as an Non-Executive Independent Director.	Ms. Sonal Mattoo, DIN: 00106795 is being re-appointed as an Non-Executive Independent Director.
2.	Date of appointment/reappointment & Terms of Appointment/re-appointment.	Re-appointed by Board in its meeting held on today i.e. 08 th August, 2025, for a period of five (5) consecutive years commencing from the conclusion of 30 th Annual General Meeting of the Company, subject to approval of Members of the Company at the ensuing AGM.	Re-appointed by Board in its meeting held on today i.e. 08 th August, 2025, for a period of five (5) consecutive years commencing from the conclusion of 30 th Annual General Meeting of the Company, subject to approval of Members of the Company at the ensuing AGM.
3.	Brief Profile (in case of appointment/re-appointment)	Mr. Amit Khosla, is a Non-executive Independent Director of the Company. He holds a Bachelor's Degree in Economics (with Honours) from Delhi University and a Master's degree in Business Administration (MBA) from Kellogg Graduate School of Management, Northwestern University, Illinois, USA. He has around 24 years of experience in financial advisory in India and abroad. With specialization in financial institutions, Mr. Amit Khosla has worked in global investment banks JP	Ms. Sonal Mattoo is a non-executive Independent Director. She holds a B.A. L.L.B. (Hons) degree from the National Law School of India University, Bangalore. She has 28 years of experience in compliance relating to workplace harassment and diversity issues. She supports various clients as an independent ombudsperson, handling employee complaints via the internal dispute redressal mechanism and as an independent IC member for the Prevention



		Morgan Chase & Co and Fox-Pitt, Kelton in New York and Hong Kong. His experience in India includes working with CDC/Actis and advising offshore funds for their India investments.	of sexual harassment at the workplace issues. She has been associated with our Company since August 29, 2020
4.	Disclosure of relationships between directors (in case of appointment of a director)	NA	NA
5.	Information as required under BSE circular no. LIST/COMP/14/2018-19, dated June 20, 2018.	Mr. Amit Khosla is not debarred from holding the office of Director by any SEBI order or any other such authority.	Ms. Sonal Mattoo is not debarred from holding the office of Director by any SEBI order or any other such authority.



Annexure- C

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

Appointment of Mr. Pankaj Kumar Gupta as an Executive Director of the Company for five years with effect from August 08, 2025, subject to the approval of the Members approval in ensuing Annual General Meeting.

Details of events that need to be provided	Information of such event(s)
Reason for change viz. appointment,	Mr. Pankaj Kumar Gupta, DIN: 11232604 is being appointed as an Executive Director.
Date of appointment & Terms of Appointment.	With effect from August 08, 2025. Terms of Appointment : For the period of five years from the date of appointment subject to Members approval in ensuing Annual General Meeting.
Brief Profile	<p>Mr. Pankaj Kumar Gupta is a highly accomplished and result-driven Operations Leader with over 35 years of experience in the medical devices and manufacturing industry. As President - Operations at Poly Medicure Ltd., a leading global manufacturer of medical disposables, he brings extensive expertise in manufacturing and operations, process optimization, supply chain management, lean manufacturing, and team leadership. With a strong technical foundation built on a 4-year Tool Engineering course from Institute of Tool Room Training (ITTUP), Mr. Gupta possesses a robust understanding of precision tooling, production planning, and industrial automation. Throughout his career, he has demonstrated a proven track record of scaling operations, enhancing productivity, and driving cost efficiencies while maintaining the highest quality standards.</p> <p>Mr. Pankaj Kumar Gupta has had a long-standing association with Poly Medicure, spanning over 17 years. He joined the company as a Senior Manager on February 18, 2008, and steadily progressed through</p>



	<p>the ranks, leveraging his expertise and experience to drive growth and excellence. Prior to his appointment as Executive Director, Mr. Gupta held the designation of President (Operations), where he played a pivotal role in overseeing and optimizing the company's operational framework. His dedication, leadership, and strategic vision have been instrumental in shaping Poly Medicure's success, and his elevation to Executive Director reflects the company's recognition of his valuable contributions and leadership capabilities.</p>
Disclosure of relationships between directors (in case of appointment of a director)	NA
Information as required under BSE circular no. LIST/COMP/14/2018-19, dated June 20, 2018.	Mr. Pankaj Kumar Gupta is not debarred from holding the office of Director by any SEBI order or any other such authority.



Annexure - D

DISCLOSURE AS PER LISTING REGULATIONS READ WITH SEBI CIRCULAR NO .SEBI/HO/CFD/PoD2/CIR/P/0155 DATED NOVEMBER 11, 2024

Grant of Stock Option

Sr. No.	Particulars	Remarks
1.	Brief details of Options Granted	3,400 Options granted by the Nomination & Remuneration Committee in its meeting held on today i.e. on August 08, 2025) to the Employees as defined under the Scheme.
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021	Yes
3.	Total number of shares covered by these options	Stock Options granted under the aforesaid Grant covers 3,400 Equity Shares. 1 Option shall be entitled for conversion to only 1 Share of the Company, subject to the terms of the Scheme.
4.	Pricing formula	Pursuant to the applicable provisions of the SEBI (SBEB) Regulations 2021 and as per provisions of the existing 'ESOP Plan', the ESOPs have been granted at a price of INR 100/- i.e. discounted price to the latest available closing price prevailing on the Stock Exchange on Friday, August 08, 2025.
5.	Options Vested	Not Applicable
6.	Time within which option may be exercised	Exercise period shall not exceed 3 (Three) months from relevant Vesting date and the date after which the Options shall lapse, unless the said period is extended by the Committee in exceptional circumstances. The Options shall not Vest for a period of one year from the date of Grant. Upon the expiry of one year, the Vesting of Options shall take place over a maximum term of (4) four years as per the Scheme.
7.	Options exercised	Not Applicable
8.	Money realized by exercise of Options	Not Applicable



9.	The total number of shares arising as a result of exercise of option	Not Applicable
10.	Options lapsed	Not Applicable
11.	Variation of terms of Options	Not Applicable
12.	Brief details of significant terms	The Employee Stock Option Scheme is administered by the Nomination and Remuneration Committee of the Company. The grant of Options is based upon the eligibility criteria as mentioned in the Scheme. The granted Options, once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes in accordance with terms and conditions of the Scheme.
13.	Subsequent changes or cancellation or exercise of such options	Not Applicable
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options.	Not Applicable



Annexure- E

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

Appointment of Cost Auditor(s)

S.No.	Particular	M/s. Jai Prakash & Company, Cost Accountants
1.	Reasons for change viz appointment/reappointment,	Re-Appointment
2.	Date of Appointment/ Re-appointment & term of appointment/reappointment	Re-appointment of M/s. Jai Prakash & Company, Cost Accountants for the Financial Year 2025-26.
3.	Brief Profile (in case of appointment)	<p>M/s Jai Prakash & Co, Cost Accountant firm was established in year 2006. The firm is managed by Cost Accounting professionals with high integrity. We are a team of strongly motivated and young entrepreneurs. By applying modern management techniques, we ensure on-target delivery of our assignments.</p> <p>At present we are providing services to the Esteemed Companies belonging to various industries i.e. Pharmaceuticals, Iron & Steels, Auto Parts and Accessories, Electrical & Electronics, Engineering, Chemicals, Textiles, Construction, Rubbers, Railways.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	NA